Marijuana, the endocannabinoid system and the female reproductive system

Yale Journal of Biology and Medicine

Volumn 89, Issue 2, 2016, Pages 175-191

  Brents, Lisa K ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Endocannabinoid system; Estrogen; Female reproduction; Fertility; HPO axis; Marijuana; Menstrual cycle; Progesterone

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; ENDOCANNABINOID; FATTY ACID AMIDASE; FOLLITROPIN; GONADORELIN; LUTEINIZING HORMONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTIRELIN; PROGESTERONE;

ADENOHYPOPHYSIS; BIRTH; CANNABIS USE; CONCEPTION; ENZYME ACTIVATION; ESTROGEN SYNTHESIS; FEMALE; FEMALE FERTILITY; FEMALE GENITAL SYSTEM; FOLLITROPIN RELEASE; GONADORELIN RELEASE; HORMONAL REGULATION; HUMAN; HYPOTHALAMIC PITUITARY OVARIAN AXIS; LACTATION; LUTEINIZING HORMONE RELEASE; MENSTRUAL CYCLE; NONHUMAN; PREGNANCY TERMINATION; PROGESTERONE SYNTHESIS; PROTEIN EXPRESSION; REPRODUCTION; REVIEW; CHEMISTRY; DRUG EFFECTS; FERTILITY; METABOLISM; PHYSIOLOGY;

CANNABIS; ENDOCANNABINOIDS; FEMALE; FERTILITY; HUMANS; MENSTRUAL CYCLE; PROGESTERONE;

EID: 84976382035     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. WHO. world Health Organization Substance Abuse Facts--Cannabis [internet]. Available from: http://www.who.int/substance:abuse/facts/cannabis/en/
2. Desilver D. Nearly half of adults say they’ve tried marijuana, but not recently. Pew Research [internet]. Available from: http://www.pewresearch.org/fact-tank/2013/06/03/morethan-a-third-of-adults-say-theyve-tried-pot-but-not-recently/
3. Saad L. in U.S., 38% Have Tried Marijuana, Little Changed Since '80s. Princeton, NJ: Gallup [internet]. 2 Aug 2013 [revised Have Tried Marijuana; cited 22 Nov 2015]. Available from: http://www.gallup.com/poll/163835/tried-marijuanalittle-changed-80s.aspxEnglish.
4. Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. 2015. Report No.: HHS Publication No. SMA 15-4927, NSDUB Series H-50 [internet]. Available from: http://www.samhsa.gov/data
5. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. Report No.: NSDUH Series H-48, HHS, Publication No. (SMA) 14-4863 [internet]. Available from: http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFwHTML2013/web/NSDUHresults2013.pdf
6. Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, Hasin DS. Epidemiology of DSM-5 drug use disorder: Results from the national epidemiologic survey on alcohol and related conditions-iii. JAMA Psychiatry. 2015;18:1-9.
7. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2002-2012. National Admission to Substance Abuse Treatment Services. Rockville, Maryland: SAMHSA; 2014. Report No.: BHSiS Series S-71, HHS Publication No. (SMA) 14-4850
8. Craft RM. Sex differences in behavioral effects of cannabinoids. Life Sci. 2005;77(20):2471-8.
9. Herrmann ES, weerts EM, vandrey R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Exp Clin Psychopharmacol. 2015;23(6):415-21.
10. Sherwood RA, Keating J, Kavvadia V, Greenough A, Peters TJ. Substance misuse in early pregnancy and relationship to fetal outcome. Eur J Pediatr. 1999;158(6):488-92.
11. Garcia-Serra J, Ramis J, Simo S, Joya X, Pichini S, vall O, Garcia-Algar O. Alternative biological materials to detect prenatal exposure to drugs of abuse in the third trimester of pregnancy. An Pediatr (Barc). 2012;77(5):323-8.
12. Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the united states during 1996-1998. Obstet Gynecol. 2003;101(2):374-9.
13. Terranova PF. The Female Reproductive System in: Rhoades RA, Tanner GA, editors. Medical Physiology. 2nd ed. Baltimore, Maryland: Lippincott williams & wilkins; 2003; p. 667-683.
14. Jukic AM, weinberg CR, Baird DD, wilcox AJ. Lifestyle and reproductive factors associated with follicular phase length. J womens Health (Larchmt). 2007;16(9):1340-7.
15. Mueller BA, Daling JR, weiss NS, Moore DE. Recreational drug use and the risk of primary infertility. Epidemiology. 1990;1(3):195-200.
16. Bauman J. Marihuana and the Female Reproductive System Testimony before the Subcommittee on Criminal Justice of the Committee on the Judiciary, U.S. Senate, Health Consequences of Marihuana Use [internet].1980; p.85-88. Available from: http://babel.hathitrust.org/cgi/pt?id=pur1.32754078039595;view=1up;seq=1
17. Smith CG, Asch RH. Acute, Short-Term and Chronic Effects of Marijuana on the Female Primate Reproductive Function in Marijuana Effects on the Endocrine and Reproductive Systems. in: Braude MC; Ludford JP, editors. NiDA Research Monograph 44 ed. Rockville, Maryland: National institute on Drug Abuse Office of Science; 1984.
18. Asch RH, Smith CG, Siler-Khodr TM, Pauerstein CJ. Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (macaca mulatta). J Clin Endocrinol Metab. 1981;52(1):50-5.
19. Lefever TW, Marusich JA, Antonazzo KR, Wiley JL. Evaluation of wiN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model. Pharmacol Biochem Behav. 2014;118:30-5.
20. Asch RH, Smith CG, Siler-Khodr TM, Pauerstein CJ. Effects of delta 9-tetraphydrocannabinol administration on gonadal steroidogenic activity in vivo. Fertil Steril. 1979;32(5):576-82.
21. Mendelson JH, Mello NK, Ellingboe J. Acute effects of marihuana smoking on prolactin levels in human females. J Pharmacol Exp Ther. 1985;232(1):220-2.
22. Mendelson JH, Mello NK, Ellingboe J, Skupny AS, Lex BW, Griffin M. Marihuana smoking suppresses luteinizing hormone in women. J Pharmacol Exp Ther. 1986;237(3):862-6.
23. Fraser HM, Nestor JJ, Jr, Vickery BH. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin. Endocrinology. 1987;121(2):612-8.
24. Almirez RG, Smith CG, Asch RH. The effects of marijuana extract and delta 9-tetrahydrocannabinol on luteal function in the rhesus monkey. Fertil Steril. 1983;39(2):212-7.
25. Smith CG, Besch NF, Smith RG, Besch PK. Effect of tetrahydrocannabinol on the hypothalamic-pituitary axis in the ovariectomized rhesus monkey. Fertil Steril. 1979;31(3):335-9.
26. Smith CG, Almirez RG, Berenberg J, Asch RH. Tolerance develops to the disruptive effects of delta 9-tetrahydrocannabinol on primate menstrual cycle. Science. 1983;219(4591):1453-5.
27. Smith RG, Besch NF, Besch PK, Smith CG. inhibition of gonadotropin by delta9-tetrahydrocannabinol:Mediation by steroid receptors? Science. 1979;204(4390):325-7.
28. Asch RH, Smith CG, Siler-Khodr TM, Pauerstein CJ. Acute decreases in serum prolactin concentrations caused by delta 9-tetrahydrocannabinol in nonhuman primates. Fertil Steril. 1979;32(5):571-5.
29. Lynch WJ, Sofuoglu M. Role of progesterone in nicotine addiction: Evidence from initiation to relapse. Exp Clin Psychopharmacol. 2010;18(6):451-61.
30. Vallee M, Vitiello S, Bellocchio L, Hebert-Chatelain E, Monlezun S, Martin-Garcia E, Kasanetz F, Baillie GL, Panin F, Cathala A, Roullot-Lacarriere V, Fabre S, Hurst DP, Lynch DL, Shore DM, Deroche-Gamonet V, Spampinato U, Revest JM, Maldonado R, Reggio PH, Ross RA, Marsicano G, Piazza PV. Pregnenolone can protect the brain from cannabis intoxication. Science. 2014;343(6166):94-8.
31. Evans SM, Haney M, Foltin RW. The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology (Berl). 2002;159(4):397-406.
32. Sofuoglu M, Dudish-Poulsen S, Nelson D, Pentel PR, Hatsukami DK. Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. Exp Clin Psychopharmacol. 1999;7(3):274-83.
33. Justice AJ, de Wit H. Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology (Berl). 1999;145(1):67-75.
34. White TL, Justice AJ, de Wit H. Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav. 2002;73(4):729-41.
35. Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol. 2007;7(1):69-76.
36. Sofuoglu M, Mouratidis M, Mooney M. Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers. Psychoneuroendocrinology. 2011;36(1):123-32.
37. Sinha R, Fox H, Hong Ki, Sofuoglu M, Morgan PT, Bergquist KT. Sex steroid hormones, stress response, and drug craving in cocaine-dependent women: implications for relapse susceptibility. Exp Clin Psychopharmacol. 2007;15(5):445-52.
38. Griffin ML, Mendelson JH, Mello NK, Lex BW. Marihuana use across the menstrual cycle. Drug Alcohol Depend. 1986;18(2):213-24.
39. Lex BW, Mendelson JH, Bavli S, Harvey K, Mello NK. Effects of acute marijuana smoking on pulse rate and mood states in women. Psychopharmacology (Berl). 1984;84(2):178-87.
40. Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. Cannabinoid self-administration in rats: Sex differences and the influence of ovarian function. Br J Pharmacol. 2007;152(5):795-804.
41. Fattore L, Spano MS, Altea S, Fadda P, Fratta W. Drug-and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones. Br J Pharmacol. 2010;160(3):724-35.
42. Daniel JM, Winsauer PJ, Brauner IN, Moerschbaecher JM. Estrogen improves response accuracy and attenuates the disruptive effects of delta9-THC in ovariectomized rats responding under a multiple schedule of repeated acquisition and performance. Behav Neurosci. 2002;116(6):989-98.
43. Craft RM, Leitl MD. Gonadal hormone modulation of the behavioral effects of Delta9-tetrahydrocannabinol in male and female rats. Eur J Pharmacol. 2008;578(1):37-42.
44. Wakley AA, Craft RM. Antinociception and sedation following intracerebroventricular administration of delta(9)-tetrahydrocannabinol in female vs. male rats. Behav Brain Res. 2011;216(1):200-6.
45. Tseng AH, Harding JW, Craft RM. Pharmacokinetic factors in sex differences in delta 9-tetrahydrocannabinol-induced behavioral effects in rats. Behav Brain Res. 2004;154(1):77-83.
46. Marusich JA, Craft RM, Lefever TW, Wiley JL. The impact of gonadal hormones on cannabinoid dependence. Exp Clin Psychopharmacol. 2015;23(4):206-16.
47. Wakley AA, Wiley JL, Craft RM. Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat. Drug Alcohol Depend. 2014;143:22-8.
48. Wakley AA, Wiley JL, Craft RM. Gonadal hormones do not alter the development of antinociceptive tolerance to delta-9-tetrahydrocannabinol in adult rats. Pharmacol Biochem Behav. 2015;133:111-21.
49. Ko JY, Farr SL, Tong VT, Creanga AA, Callaghan WM. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol. 2015;213(2):201.
50. Khare M, Taylor AH, Konje JC, Bell SC. Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006;12(5):321-33.
51. Costa MA, Fonseca BM, Marques F, Teixeira NA, Correiada-Silva G. The psychoactive compound of cannabis sativa, delta(9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015;334:94-103.
52. Rosenkrantz H, Esber HJ. Cannabinoid-induced hormone changes in monkeys and rats. J Toxicol Environ Health. 1980;6(2):297-313.
53. Braustein GD, Buster JE, Soares JR, Gross SJ. Pregnancy hormone concentrations in marijuana users. Life Sci. 1983;33(2):195-9.
54. Fried PA, Watkinson B, Willan A. Marijuana use during pregnancy and decreased length of gestation. Am J Obstet Gynecol. 1984;150(1):23-7.
55. Hayatbakhsh MR, Flenady VJ, Gibbons KS, Kingsbury AM, Hurrion E, Mamun AA, Najman JM. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res. 2012;71(2):215-9.
56. Varner MW, Silver RM, Rowland Hogue CJ, Willinger M, Parker CB, Thorsten VR, Goldenberg RL, Saade GR, Dudley DJ, Coustan D, Stoll B, Bukowski R, Koch MA, Conway D, Pinar H, Reddy UM, Eunice Kennedy Shriver National institute of Child Health and Human Development Stillbirth Collaborative Research Network. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol. 2014;123(1):113-25.
57. Asch RH, Smith CG. Effects of delta 9-THC, the principal psychoactive component of marijuana, during pregnancy in the rhesus monkey. J Reprod Med. 1986;31(12):1071-81.
58. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. an emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol. 2001;23(1):1-11.
59. Brents LK. Correlates and consequences of prenatal cannabis exposure (PCE): identifying and characterizing vulnerable maternal populations and determining outcomes for exposured offspring. in: Preedy v, editor. Handbook of Cannabis and Related Pathologies. Cambridge, MA: Academic Press, forthcoming, 2017.
60. Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from cannabis sativa. Biol Pharm Bull. 2011;34(5):774-8.
61. Butovsky E, Juknat A, Elbaz J, Shabat-Simon M, Eilam R, Zangen A, Altstein M, Vogel Z. Chronic exposure to Delta9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas. Mol Cell Neurosci. 2006;31(4):795-804.
62. Tyrey L, Murphy LL. inhibition of suckling-induced milk ejections in the lactating rat by delta 9-tetrahydrocannabinol. Endocrinology. 1988;123(1):469-72.
63. Raine JM, Wing DR, Paton WD. The effects of delta1-tetrahydrocannabinol on mammary gland growth, enzyme activity and plasma prolactin levels in the mouse. Eur J Pharmacol. 1978;51(1):11-7.
64. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. Mol Pharmacol. 2000;57(5):1045-50.
65. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res. 2009;60(2):77-84.
66. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516-25.
67. Murataeva N, Straiker A, Mackie K. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol. 2014;171(6):1379-91.
68. Gorzalka BB, Hill MN. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1575-85.
69. Li C, Jones PM, Persaud SJ. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther. 2011;129(3):307-20.
70. Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs. 2010;70(18):2409-38.
71. Rossi F, Bellini G, Luongo L, Torella M, Mancusi S, De Petrocellis L, Petrosino S, Siniscalco D, Orlando P, Scafuro M, Colacurci N, Perrotta S, Nobili B, Di Marzo V, Maione S, Endocannabinoid Research Group (ERG), italy. The endovanilloid/ endocannabinoid system: A new potential target for osteoporosis therapy. Bone. 2011;48(5):997-1007.
72. Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: Role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets. 2010;9(5):564-73.
73. Kunos G, Tam J. The case for peripheral CB(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol. 2011;163(7):1423-31.
74. Bari M, Battista N, Pirazzi V, Maccarrone M. The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci (Landmark Ed). 2011;16:498-516.
75. Bagavandoss P, Grimshaw S. Temporal and spatial distribution of the cannabinoid receptors (CB1, CB2) and fatty acid amide hydroxylase in the rat ovary. Anat Rec (Hoboken). 2010;293(8):1425-32.
76. El-Talatini MR, Taylor AH, Elson JC, Brown L, Davidson AC, Konje JC. Localisation and function of the endocannabinoid system in the human ovary. PLoS One. 2009;4(2):e4579.
77. Horne AW, Phillips JA, 3rd, Kane N, Lourenco PC, McDonald SE, Williams AR, Simon C, Dey SK, Critchley HO. CB1 expression is attenuated in fallopian tube and decidua of women with ectopic pregnancy. PLoS One. 2008;3(12):e3969.
78. Brighton PJ, Marczylo TH, Rana S, Konje JC, Willets JM. Characterization of the endocannabinoid system, CB(1) receptor signalling and desensitization in human myometrium. Br J Pharmacol. 2011;164(5):1479-94.
79. Taylor AH, Abbas MS, Habiba MA, Konje JC. Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. Histochem Cell Biol. 2010;133(5):557-65.
80. Gentilini D, Besana A, Vigano P, Dalino P, Vignali M, Melandri M, Busacca M, Di Blasio AM. Endocannabinoid system regulates migration of endometrial stromal cells via cannabinoid receptor 1 through the activation of Pi3K and ERK1/2 pathways. Fertil Steril. 2010;93(8):2588-93.
81. Gentilini D, Busacca M, Di Francesco S, Vignali M, Vigano P, Di Blasio AM. Pi3K/akt and ERK1/2 signalling pathways are involved in endometrial cell migration induced by 17beta-estradiol and growth factors. Mol Hum Reprod. 2007;13(5):317-22.
82. Lazzarin N, Valensise H, Bari M, Ubaldi F, Battista N, Finazzi-Agro A, Maccarrone M. Fluctuations of fatty acid amide hydrolase and anandamide levels during the human ovulatory cycle. Gynecol Endocrinol. 2004;18(4):212-8.
83. El-Talatini MR, Taylor AH, Konje JC. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil Steril. 2010;93(6):1989-96.
84. Gonzalez S, Bisogno T, Wenger T, Manzanares J, Milone A, Berrendero F, Di Marzo V, Ramos JA, Fernandez-Ruiz JJ. Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun. 2000;270(1):260-6.
85. Scorticati C, Fernandez-Solari J, De Laurentiis A, Mohn C, Prestifilippo JP, Lasaga M, Seilicovich A, Billi S, Franchi A, McCann SM, Rettori V. The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc Natl Acad Sci U S A. 2004;101(32):11891-6.
86. Dall'Aglio C, Millan P, Maranesi M, Rebollar PG, Brecchia G, Zerani M, Gobbetti A, Gonzalez-Mariscal G, Boiti C. Expression of the cannabinoid receptor type 1 in the pituitary of rabbits and its role in the control of LH secretion. Domest Anim Endocrinol. 2013;45(4):171-9.
87. Riebe CJ, Hill MN, Lee TT, Hillard CJ, Gorzalka BB. Estrogenic regulation of limbic cannabinoid receptor binding. Psychoneuroendocrinology. 2010;35(8):1265-9.
88. Wang H, Matsumoto H, Guo Y, Paria BC, Roberts RL, Dey SK. Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. Proc Natl Acad Sci U S A. 2003;100(25):14914-9.
89. Das SK, Paria BC, Chakraborty I, Dey SK. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci U S A. 1995;92(10):4332-6.
90. Fonseca BM, Correia-da-Silva G, Almada M, Costa MA, Teixeira NA. The endocannabinoid system in the postimplantation period: A role during decidualization and placentation. int J Endocrinol. 2013;2013:510540.
91. Sun X, Dey SK. Aspects of endocannabinoid signaling in periimplantation biology. Mol Cell Endocrinol. 2008;286(1-2 Suppl 1):S3-11.
92. Paria BC, Ma W, Andrenyak DM, Schmid PC, Schmid HH, Moody DE, Deng H, Makriyannis A, Dey SK. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. Biol Reprod. 1998;58(6):1490-5.
93. Xie H, Sun X, Piao Y, Jegga AG, Handwerger S, Ko MS, Dey SK. Silencing or amplification of endocannabinoid signaling in blastocysts via CB1 compromises trophoblast cell migration. J Biol Chem. 2012;287(38):32288-97.
94. Costa MA, Fonseca BM, Keating E, Teixeira NA, Correiada-Silva G. 2-arachidonoylglycerol effects in cytotrophoblasts: Metabolic enzymes expression and apoptosis in Bewo cells. Reproduction. 2014;147(3):301-11.
95. Costa MA, Keating E, Fonseca BM, Teixeira NA, Correiada-Silva G. 2-arachidonoylglycerol impairs human cytotrophoblast cells syncytialization: influence of endocannabinoid signalling in placental development. Mol Cell Endocrinol. 2015;399:386-94.
96. Costa MA, Fonseca BM, Teixeira NA, Correia-da-Silva G. The endocannabinoid anandamide induces apoptosis in cytotrophoblast cells: involvement of both mitochondrial and death receptor pathways. Placenta. 2015;36(1):69-76.
97. Habayeb OM, Taylor AH, Bell SC, Taylor DJ, Konje JC. Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation. Endocrinology. 2008;149(10):5052-60.
98. Habayeb OM, Taylor AH, Evans MD, Cooke MS, Taylor DJ, Bell SC, Konje JC. Plasma levels of the endocannabinoid anandamide in women--a potential role in pregnancy maintenance and labor? J Clin Endocrinol Metab. 2004;89(11):5482-7.
99. Mitchell MD, Sato TA, Wang A, Keelan JA, Ponnampalam AP, Glass M. Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue-and CB1-receptor-specific mechanism. Am J Physiol Endocrinol Metab. 2008;294(2):E352-6.
100. Chamley LW, Bhalla A, Stone PR, Liddell H, O'Carroll S, Kearn C, Glass M. Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage. Placenta. 2008;29(11):970-5.
101. Taylor AH, Finney M, Lam PM, Konje JC. Modulation of the endocannabinoid system in viable and non-viable first trimester pregnancies by pregnancy-related hormones. Reprod Biol Endocrinol. 2011;9:152.
102. Trabucco E, Acone G, Marenna A, Pierantoni R, Cacciola G, Chioccarelli T, Mackie K, Fasano S, Colacurci N, Meccariello R, Cobellis G, Cobellis L. Endocannabinoid system in first trimester placenta: Low FAAH and high CB1 expression characterize spontaneous miscarriage. Placenta. 2009;30(6):516-22.
103. Fonseca BM, Correia-da-Silva G, Taylor AH, Lam PM, Marczylo TH, Konje JC, Teixeira NA. Characterisation of the endocannabinoid system in rat haemochorial placenta. Reprod Toxicol. 2012;34(3):347-56.
104. Park B, Gibbons HM, Mitchell MD, Glass M. identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta. 2003;24(10):990-5.
105. Chan HW, McKirdy NC, Peiris HN, Rice GE, Mitchell MD. The role of endocannabinoids in pregnancy. Reproduction. 2013;146(3):R101-9.
106. Lopez HH, Webb SA, Nash S. Cannabinoid receptor antagonism increases female sexual motivation. Pharmacol Biochem Behav. 2009;92(1):17-24.
107. Mani SK, Mitchell A, O'Malley BW. Progesterone receptor and dopamine receptors are required in delta 9-tetrahydrocannabinol modulation of sexual receptivity in female rats. Proc Natl Acad Sci U S A. 2001;98(3):1249-54.
108. National Center for Biotechnology information. PubChem Compound Database; CiD=16078 (Δ9-THC), https://pubchem.ncbi.nlm.nih.gov/compound/16078 (accessed May 3, 2016).
109. National Center for Biotechnology information. PubChem Compound Database; CiD=5311501 (wiN 55,212-2), https://pubchem.ncbi.nlm.nih.gov/compound/5311501 (accessed May 3, 2016).
110. National Center for Biotechnology information. PubChem Compound Database; CiD=104850 (Rimonabant), https://pubchem.ncbi.nlm.nih.gov/compound/104850 (accessed May 3, 2016).
111. National Center for Biotechnology information. PubChem Compound Database; CiD=2125 (AM-251), https://pubchem.ncbi.nlm.nih.gov/compound/2125 (accessed May 3, 2016).
112. National Center for Biotechnology information. PubChem Compound Database; CiD=8955 (Pregnenolone), https://pubchem.ncbi.nlm.nih.gov/compound/8955 (accessed May 3, 2016).
113. National Center for Biotechnology information. PubChem Compound Database; CiD=5994 (Progesterone), https://pubchem.ncbi.nlm.nih.gov/compound/5994 (accessed May 3, 2016).
114. National Center for Biotechnology information. PubChem Compound Database; CiD=5757 (Estradiol), https://pubchem.ncbi.nlm.nih.gov/compound/5757 (accessed May 3, 2016).